Summary: ZYNE has a cannabidiol gel it is running through various trials. The company and
Summary: Exela reported Q4 results highlighted by continued weakness in sales and earnings. Management believes
Summary: Today, we revisit small biopharma Zynerba Pharmaceuticals for the first time in just over
Summary: Aerie has 2 marketed products and decent pipeline after a recent acquisition. Aerie unfortunately
Summary: Indonesia Energy has filed proposed terms for a $15 million U.S. IPO of its
Summary: Today, we revisit ocular concern Aerie Pharmaceuticals. The company has struggled as a newly
Summary: Indonesia Energy has filed its initial registration statement for a U.S. IPO. The firm
Summary: Sell-side estimates for this quarter’s revenue are too high and have begun to be
Summary: Recent “failure” of lead compound opens up new windows. Let’s talk about the pipeline;
Summary: We revisit Aerie Pharmaceuticals. The stock has had a wild ride, getting crushed in the